Boardroom Alpha
Boardroom Alpha
CJMB · Current Report (Form 8-K) · Filed May 27, 2026

Callan Jmb Inc — Current Report (Form 8-K)

Form
8-K
Filed
May 27, 2026
Period
May 26, 2026
Ticker
CJMB
Accession
0001493152-26-025298
Boardroom Alpha · Filing insights

Callan JMB activates ATM with Alexander Capital to raise up to $5M; 3% commission, expenses, for working capital.

About Callan Jmb Inc
Market cap
$4M
1Y TSR
−80.4%
Board grade
D
Sector
Industrials
CEO
Wayne D Williams
Last annual meeting: Dec 29, 2025 · View full Callan Jmb Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 26, 2026

 

Callan JMB Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   001-42506   99-0931141

(State or other jurisdiction 

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

244 Flightline Drive

Spring Branch, Texas

  78070
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (830) 438-0395

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value   CJMB   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On May 26, 2026, Callan JMB Inc. (the “Company”) entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Alexander Capital, L.P. (“Alexander Capital”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Alexander Capital shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $5,000,000.

 

Sales of the Common Stock, if any, pursuant to the Sales Agreement will be made in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the Nasdaq Capital Market, on any other existing trading market for the Common Stock or to or through a market maker other than on an exchange. Alexander Capital is not required to sell any specific number or dollar amount of shares of Common Stock, but will act as a sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Alexander Capital and the Company. With the Company’s prior written approval, Alexander Capital may also sell shares of Common Stock in privately negotiated transactions.

 

The Company will pay Alexander Capital a commission equal to 3.0% of the gross proceeds from each sale of shares of Common Stock sold through Alexander Capital under the Sales Agreement. The Company has also agreed to reimburse Alexander Capital for certain specified expenses, including the fees and disbursements of its counsel in an amount not to exceed $50,000 in connection with the establishment of the at-the-market offering, and thereafter, an amount not to exceed $3,000 on a quarterly basis.

 

The Company intends to use the net proceeds from sales of Common Stock under the Sales Agreement for working capital and general corporate purposes.

 

The Sales Agreement contains customary representations, warranties and covenants by the Company, indemnification obligations of the Company and Alexander Capital, and other obligations of the parties. The offering of Common Stock pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all of the shares of Common Stock subject to the Sales Agreement or (ii) the termination of the Sales Agreement as permitted therein. Either party may terminate the Sales Agreement upon prior written notice to the other party as specified in the Sales Agreement.

 

The shares of Common Stock to be offered and sold under the Sales Agreement, if any, will be issued pursuant to the Company’s registration statement on Form S-3 (File No. 333-296253), filed with the Securities and Exchange Commission (the “SEC”) on May 26, 2026, including a prospectus supplement dated May 26, 2026 relating to the offering of up to $5,000,000 of shares of Common Stock pursuant to the Sales Agreement.

 

The foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the future financial performance of the Company and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

 

In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “believes,” “estimates,” “projects,” “potential,” “continues,” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding the Company’s intent to submit a plan to regain compliance with the Stockholders’ Equity Requirement within 45 calendar days and the Company’s ability to regain compliance with the Stockholders’ Equity Requirement by the deadline imposed by Nasdaq.

 

These forward-looking statements reflect the Company’s current expectations and projections based on information available as of the date of this Current Report on Form 8-K and are subject to a number of risks and uncertainties, including, but not limited to, general economic, financial, and business conditions; the Company’s ability to successfully implement its strategic initiatives; supply chain disruptions; regulatory compliance and legal proceedings; and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

 

The Company cautions investors that forward-looking statements are not guarantees of future performance and actual results may differ materially from those projected. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

 

 

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
10.1   At-The-Market Issuance Sales Agreement, dated May 26, 2026, between Callan JMB Inc. and Alexander Capital, L.P. (incorporated by reference to Exhibit 1.2 to the Company’s Registration Statement on Form S-3 filed with the SEC on May 26, 2026)
104   Cover Page Interactive Data File (embedded with the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 26, 2026 Callan JMB Inc.
     
  By: /s/ Wayne Williams
  Name: Wayne Williams
  Title: Chief Executive Officer

 

 

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Callan Jmb Inc (CJMB)

Reference

Frequently asked questions

When did Callan Jmb Inc file this 8-K?
Callan Jmb Inc (CJMB) filed this Current Report (Form 8-K) with the SEC on May 27, 2026. The accession number assigned by EDGAR is 0001493152-26-025298.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Callan JMB activates ATM with Alexander Capital to raise up to $5M; 3% commission, expenses, for working capital. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Callan Jmb Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Callan Jmb Inc has filed under CIK 2032545, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer